AMNEAL PHARMACEUTICALS INC AMRX
ASignal's systematic analysis rates AMRX as Neutral.
Reflects the latest available analysis · analyzed Nov 10, 2026
The case on AMRX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- RSI near neutral zone (58.56), not overbought
- Price above SMA20 and SMA50, indicating uptrend
- Strong return on equity (70.00%)
- Revenue growth of 10.00% YoY
- Forward P/E of 17.21x suggests better future valuation
- MACD below signal line, indicating weakening momentum
- Negative free cash flow (-$42.07M)
- High debt-to-equity ratio (5.12x)
- High P/E ratio (53.05x) relative to peers
- High price-to-book ratio (13.41x)
- No Reddit mentions, indicating low retail sentiment
See the full verdict on AMRX
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes AMRX
Most investors never get a second opinion, let alone several. ASignal runs AMRX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.